Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists (original) (raw)

• Schoepp DD, Conn PJ. Metabotropic glutamate receptors. Pharmacol Biochem Behav 2002; 74(1): 255–6
  Article PubMed CAS Google Scholar
• Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004; 174(1): 39–44
  Article CAS Google Scholar
• Krystal JH, Petrakis IL, Mason G, et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003; 99(1): 79–94
  Article PubMed CAS Google Scholar
• Krystal JH, Moghaddam B. Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia. In: Hirsch S, Weinberger D, editors. Schizophrenia. 3rd ed. Oxford (UK): Blackwell Science, 2010
  Google Scholar
• Chambers AC, Bremner JD, Moghaddam B, et al. Glutamate and post-traumatic stress disorder: toward a neurobiology of dissociation. Semin Clin Neuropsychiatry 1999; 4(4): 274–81
  PubMed CAS Google Scholar
• Sanacora G, Zarate CAJ, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev: Drug Discov 2008; 7(5): 426–37
  Article CAS Google Scholar
• Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9(11): 984–97, 979
  Article PubMed CAS Google Scholar
• Gupta DS, McCullumsmith RE, Beneyto M, et al. Meta-botropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005; 57(3): 123–31
  Article PubMed CAS Google Scholar
• Ohnuma T, Augood SJ, Arai H, et al. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998; 56(1-2): 207–17
  Article PubMed CAS Google Scholar
• Sartorius LJ, Weinberger DR, Hyde TM, et al. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008; 33(11): 2626–34
  Article PubMed CAS Google Scholar
• Corti C, Crepaldi L, Mion S, et al. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry 2007; 62(7): 747–55
  Article PubMed CAS Google Scholar
• Tkachev D, Mimmack ML, Huffaker SJ, et al. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 2007; 10(4): 557–63
  Article PubMed CAS Google Scholar
• Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452(7183): 93–7
  Article PubMed CAS Google Scholar
• Richardson-Burns SM, Haroutunian V, Davis KL, et al. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 2000; 47(1): 22–8
  Article PubMed CAS Google Scholar
• Crook JM, Akil M, Law BC, et al. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann’s area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 2002; 7(2): 157–64
  Article PubMed CAS Google Scholar
• Pietraszek M, Gravius A, Schafer D, et al. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005; 49(1): 73–85
  Article PubMed CAS Google Scholar
• Maeda J, Suhara T, Okauchi T, et al. Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex. Neurosci Lett 2003; 336(3): 171–4
  Article PubMed CAS Google Scholar
• Chan MH, Chiu PH, Sou JH, et al. Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology (Berl) 2008; 198(1): 141–8
  Article CAS Google Scholar
• Lecourtier L, Homayoun H, Tamagnan G, et al. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007; 62(7): 739–46
  Article PubMed CAS Google Scholar
• Homayoun H, Stefani MR, Adams BW, et al. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004; 29(7): 1259–69
  Article PubMed CAS Google Scholar
• Pietraszek M, Rogoz Z, Wolfarth S, et al. Opposite influence of MPEP, an mGluR5 antagonist, on the locomotor hyperactivity induced by PCP and amphetamine. J Physiol Pharmacol 2004; 55(3): 587–93
  PubMed CAS Google Scholar
• Campbell UC, Lalwani K, Hernandez L, et al. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 2004; 175(3): 310–8
  Article CAS Google Scholar
• Imre G, Salomons A, Jongsma M, et al. Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 2006; 84(3): 392–9
  Article PubMed CAS Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine ef-fects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281(5381): 1349–52
  Article PubMed CAS Google Scholar
• Woolley ML, Pemberton DJ, Bate S, et al. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008; 196(3): 431–40
  Article CAS Google Scholar
• Rorick-Kehn LM, Johnson BG, Knitowski KM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007; 193(1): 121–36
  Article CAS Google Scholar
• Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999; 291(1): 161–70
  PubMed CAS Google Scholar
• Cartmell J, Monn JA, Schoepp DD. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 2000; 148(4): 423–9
  Article CAS Google Scholar
• Fell MJ, Johnson BG, Svensson KA, et al. Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY 404039. J Pharmacol Exp Ther 2008; 326(1): 209–17
  Article PubMed CAS Google Scholar
• Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005; 93(4): 1989–2001
  Article PubMed CAS Google Scholar
• Clark M, Johnson BG, Wright RA, et al. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacol Biochem Behav 2002; 73(2): 339–46
  Article PubMed CAS Google Scholar
• Harich S, Gross G, Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007; 192(4): 511–9
  Article CAS Google Scholar
• Schreiber R, Lowe D, Voerste A, et al. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 2000; 388(2): R3–4
  Article PubMed CAS Google Scholar
• Olszewski RT, Wegorzewska MM, Monteiro AC, et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008; 63(1): 86–91
  Article PubMed CAS Google Scholar
• Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008; 33(7): 1760–72
  Article PubMed CAS Google Scholar
• Robbins MJ, Starr KR, Honey A, et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res 2007; 1152: 215–27
  Article PubMed CAS Google Scholar
• Benneyworth MA, Xiang Z, Smith RL, et al. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 2007; 72(2): 477–84
  Article PubMed CAS Google Scholar
• Marek GJ, Wright RA, Schoepp DD, et al. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 2000; 292(1): 76–87
  PubMed CAS Google Scholar
• Galici R, Echemendia NG, Rodriguez AL, et al. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005; 315(3): 1181–7
  Article PubMed CAS Google Scholar
• Kinney GG, O’Brien JA, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005; 313(1): 199–206
  Article PubMed CAS Google Scholar
• Homayoun H, Moghaddam B. Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A 2008; 105(46): 18041–6
  Article PubMed CAS Google Scholar
• Cartmell J, Monn JA, Schoepp DD. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 2000; 400(2-3): 221–4
  Article PubMed CAS Google Scholar
• van Berckel BN, Kegeles LS, Waterhouse R, et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 2006; 31(5): 967–77
  Article PubMed CAS Google Scholar
• Homayoun H, Moghaddam B. Bursting of prefrontal cor-tex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex 2006; 16(1): 93–105
  Article PubMed Google Scholar
• Devon RS, Anderson S, Teague PW, et al. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 2001; 6(3): 311–4
  Article PubMed CAS Google Scholar
• Tu JC, Xiao B, Naisbitt S, et al. Coupling of mGluR/ Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999; 23(3): 583–92
  Article PubMed CAS Google Scholar
• Gauthier J, Champagne N, Lafreniere RG, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A 2010; 107: 7863–8
  Article PubMed CAS Google Scholar
• Luccini E, Musante V, Neri E, et al. Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals. Br J Pharmacol 2007; 151(7): 1087–94
  Article PubMed CAS Google Scholar
• Choe ES, Shin EH, Wang JQ. Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo. Neurosci Lett 2006; 394(3): 246–51
  Article PubMed CAS Google Scholar
• Awad H, Hubert GW, Smith Y, et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000; 20(21): 7871–9
  PubMed CAS Google Scholar
• Bruno V, Copani A, Knopfel T, et al. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neurophar-macology 1995; 34(8): 1089–98
  Article CAS Google Scholar
• Jia Z, Lu Y, Henderson J, et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR 5. Learn Mem 1998; 5(4-5): 331–43
  PubMed CAS Google Scholar
• Pisani A, Gubellini P, Bonsi P, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001; 106(3): 579–87
  Article PubMed CAS Google Scholar
• Alagarsamy S, Marino MJ, Rouse ST, et al. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 1999; 2(3): 234–40
  Article PubMed CAS Google Scholar
• Ugolini A, Corsi M, Bordi F. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999; 38(10): 1569–76
  Article PubMed CAS Google Scholar
• Pietraszek M, Nagel J, Gravius A, et al. The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids 2007; 32(2): 173–8
  Article PubMed CAS Google Scholar
• Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006; 11(2): 118–9
  Article PubMed CAS Google Scholar
• Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007; 78: 69–108
  Article PubMed CAS Google Scholar
• Kristiansen LV, Huerta I, Beneyto M, et al. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007; 7(1): 48–55
  Article PubMed CAS Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52(12): 998–1007
  Article PubMed CAS Google Scholar
• Koros E, Rosenbrock H, Birk G, et al. The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology 2007; 32(3): 562–76
  Article PubMed CAS Google Scholar
• Brody SA, Conquet F, Geyer MA. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 2004; 172(2): 187–95
  Article CAS Google Scholar
• Conn PJ, Lindsley CW, Jones CK. Activation of metabo-tropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009; 30(1): 25–31
  Article PubMed CAS Google Scholar
• Rodriguez AL, Williams R. Recent progress in the development of allosteric modulators of mGluR 5. Curr Opin Drug Discov Devel 2007; 10(6): 715–22
  PubMed CAS Google Scholar
• Harrison PJ, Lyon L, Sartorius LJ, et al. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22(3): 308–22
  Article PubMed CAS Google Scholar
• Joo A, Shibata H, Ninomiya H, et al. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol Psychiatry 2001; 6(2): 186–92
  Article PubMed CAS Google Scholar
• Marti SB, Cichon S, Propping P, et al. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 2002; 114(1): 46–50
  Article PubMed Google Scholar
• Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003; 13(2): 71–6
  PubMed Google Scholar
• Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004; 101(34): 12604–9
  Article PubMed CAS Google Scholar
• Chen Q, He G, Chen Q, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 2005; 73(1): 21–6
  Article PubMed Google Scholar
• Norton N, Williams HJ, Dwyer S, et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 2005; 5: 23
  Article PubMed CAS Google Scholar
• Tochigi M, Suga M, Ohashi J, et al. No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr Res 2006; 88(1-3): 260–4
  Article PubMed Google Scholar
• Albalushi T, Horiuchi Y, Ishiguro H, et al. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am J Med Genet B Neuropsychiatr Genet 2008; 147(3): 392–6
  PubMed Google Scholar
• Bishop JR, Wang K, Moline J, et al. Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2007; 17(6): 358
  Article PubMed Google Scholar
• Schwab SG, Plummer C, Albus M, et al. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study. Psychiatr Genet 2008; 18(1): 25–30
  Article PubMed Google Scholar
• Ohtsuki T, Toru M, Arinami T. Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr Genet 2001; 11(2): 79–83
  Article PubMed CAS Google Scholar
• Bray NJ, Williams NM, Bowen T, et al. No evidence for association between a non-synonymous polymorphism in the gene encoding human metabotropic glutamate receptor 7 and schizophrenia. Psychiatr Genet 2000; 10(2): 83–6
  Article PubMed CAS Google Scholar
• Bolonna AA, Kerwin RW, Munro J, et al. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res 2001; 47(1): 99–103
  Article PubMed CAS Google Scholar
• Ohtsuki T, Koga M, Ishiguro H, et al. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res 2008; 101(1-3): 9–16
  Article PubMed Google Scholar
• Takaki H, Kikuta R, Shibata H, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128(1): 6–14
  Article Google Scholar
• Marenco S, Steele SU, Egan MF, et al. Effect of metabotropic glutamate receptor 3 genotype on N-acetylas-partate measures in the dorsolateral prefrontal cortex. Am J Psychiatry 2006; 163(4): 740–2
  Article PubMed Google Scholar
• Bishop JR, Ellingrod VL, Moline J, et al. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005; 77(2-3): 253–60
  Article PubMed Google Scholar
• Wroblewska B, Wroblewski JT, Pshenichkin S, et al. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997; 69(1): 174–81
  Article PubMed CAS Google Scholar
• Bergeron R, Imamura Y, Frangioni JV, et al. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J Neurochem 2007; 100(2): 346–57
  Article PubMed CAS Google Scholar
• Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52(10): 829–36
  Article PubMed CAS Google Scholar
• Ghose S, Weickert CS, Colvin SM, et al. Glutamate car-boxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsycho-pharmacology 2004; 29(1): 117–25
  Article CAS Google Scholar
• Krystal JH, D’Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003; 169: 215–33
  Article PubMed CAS Google Scholar
• Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13(9): 1102–7
  Article PubMed CAS Google Scholar
• Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17(8): 2921–7
  PubMed CAS Google Scholar
• Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001; 15(4): 297–301
  Article PubMed CAS Google Scholar
• Post RM. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr Res 1999; 39(2): 153–8; discussion 163
  Article PubMed CAS Google Scholar
• Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66(8): 1012–5
  Article PubMed CAS Google Scholar
• Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 2005; 181(3): 415–36
  Article CAS Google Scholar
• Anand A, Charney DS, Cappiello A, et al. Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry 2000; 57: 270–6
  Article PubMed CAS Google Scholar
• Gozzi A, Large CH, Schwarz A, et al. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008; 33(7): 1690–703
  Article PubMed CAS Google Scholar
• Brody SA, Geyer MA, Large CH. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 2003; 169(3-4): 240–6
  Article CAS Google Scholar
• Farber NB, Newcomer JW, Olney JW. Lamotrigine prevents NMDA antagonist neurotoxicity. Schizophr Res 1999; 36 (1-3): 308
  Google Scholar
• Idris NF, Repeto P, Neill JC, et al. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 2005; 179(2): 336–48
  Article CAS Google Scholar
• Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical anti-psychotics in schizophrenia. Biol Psychiatry 2004; 56(6): 441–6
  Article PubMed CAS Google Scholar
• Tiihonen J, Hallikainen T, Ryynänen O-P, et al. Lamo-trigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1–6
  Article CAS Google Scholar
• Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007; 27(6): 582–9
  Article PubMed CAS Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349–52
  Article PubMed CAS Google Scholar
• Swanson CJ, Schoepp DD. The group II metabotropic glutamate receptor agonist (−)-2-oxa-4-amino-bicyclo [3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J Pharmacol Exp Ther 2002; 303(3): 919–27
  Article PubMed CAS Google Scholar
• Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, in healthy human subjects. Psychopharmacology 2005; 179(1): 303–9
  Article PubMed CAS Google Scholar
• Eli Lilly and Company. Lilly announces inconclusive phase II study results for mGlu2/3 at the International Congress on Schizophrenia Research [online]. Available from URL: http://newsroom.lilly.com/releasedetail.cfm?releaseid=373650 [Accessed 2010 May 19]
• Baker DA, Xi ZX, Shen H, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002; 22(20): 9134–41
  PubMed CAS Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64(5): 361–8
  Article PubMed CAS Google Scholar
• Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33(9): 2187–99
  Article PubMed CAS Google Scholar
• Olszewski RT, Bukhari N, Zhou J, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 2004; 89(4): 876–85
  Article PubMed CAS Google Scholar
• Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comor-bidity Survey. Arch Gen Psychiatry 1994; 51(1): 8–19
  Article PubMed CAS Google Scholar
• Amiel JA, Mathew SJ. Glutamate and anxiety disorders. Curr Psychiatry Rep 2007; 9(4): 278–83
  Article PubMed Google Scholar
• Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 2008; 14C: 89–98
  Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000
  Google Scholar
• Andrade L, Eaton WW, Chilcoat H. Lifetime comorbidity of panic attacks and major depression in a population-based study: symptom profiles. Br J Psychiatry 1994; 165(3): 363–9
  Article PubMed CAS Google Scholar
• Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry 2000; 157(1): 89–95
  PubMed CAS Google Scholar
• Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl 1998; 393: 6–11
  Article PubMed CAS Google Scholar
• Glantz MD, Anthony JC, Berglund PA, et al. Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. Psychol Med 2009; 39(8): 1365–77
  Article PubMed CAS Google Scholar
• Robinson J, Sareen J, Cox BJ, et al. Self-medication of anxiety disorders with alcohol and drugs: results from a nationally representative sample. J Anxiety Disord 2009; 23(1): 38–45
  Article PubMed Google Scholar
• Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64(7): 830–42
  Article PubMed Google Scholar
• Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 2009; 99(1–3): 248–60
  Article PubMed Google Scholar
• Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165(3): 342–51
  Article PubMed Google Scholar
• Swanson CJ, Bures M, Johnson MP, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4(2): 131–44
  Article PubMed CAS Google Scholar
• Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002; 51(10): 775–87
  Article PubMed CAS Google Scholar
• Phan KL, Fitzgerald DA, Cortese BM, et al. Anterior cin-gulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport 2005; 16(2): 183–6
  Article PubMed Google Scholar
• Pollack MH, Jensen JE, Simon NM, et al. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 739–43
  Article PubMed CAS Google Scholar
• Pittenger C, Coric V, Banasr M, et al. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008; 22(9): 761–86
  Article PubMed CAS Google Scholar
• Mathew SJ, Amiel JM, Coplan JD, et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005; 162(12): 2379–81
  Article PubMed Google Scholar
• Mathew SJ, Price RB, Mao X, et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008; 63(9): 891–8
  Article PubMed CAS Google Scholar
• Van Ameringen M, Mancini C, Pipe B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65(12): 1674–8
  Article PubMed Google Scholar
• Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29(1): 26–48
  Article PubMed CAS Google Scholar
• Krystal JH, Tolin DF, Sanacora G, et al. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today 2009; 14: 690–7
  Article PubMed CAS Google Scholar
• Davis M, Ressler K, Rothbaum BO, et al. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006; 60: 369–75
  Article PubMed CAS Google Scholar
• Norberg MM, Krystal JH, Tolin DF, et al. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118–26
  Article PubMed CAS Google Scholar
• Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136–44
  Article PubMed Google Scholar
• Camodeca N, Breakwell NA, Rowan MJ, et al. Induction of LTD by activation of group I mGluR in the dentate gyrusin vitro. Neuropharmacology 1999; 38: 1597–606
  Article PubMed CAS Google Scholar
• Popkirov SG, Manahan-Vaughan D. Involvement of the metabotropic glutamate receptor mGluR5 in NMDA receptor-dependent, learning-facilitated long-term depression in CA1 synapses. Cereb Cortex. Epub 2010 Jun 4
• Sung KW, Choi S, Lovinger DM, et al. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J Neurolphysiol 2001; 86: 2405–12
  CAS Google Scholar
• Ballard TM, Woolley ML, Prinssen E, et al. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 2005; 179(1): 218–29
  Article CAS Google Scholar
• Busse CS, Brodkin J, Tattersall D, et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004; 29(11): 1971–9
  Article PubMed CAS Google Scholar
• Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005; 315(2): 711–21
  Article PubMed CAS Google Scholar
• Pecknold JC, McClure DJ, Appeltauer L, et al. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982; 2(2): 129–33
  Article PubMed CAS Google Scholar
• Mitsukawa K, Mombereau C, Lotscher E, et al. Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 2006; 31(6): 1112–22
  PubMed CAS Google Scholar
• Fendt M, Schmid S, Thakker DR, et al. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 2008; 13(10): 970–9
  Article PubMed CAS Google Scholar
• Schoepp DD, Wright RA, Levine LR, et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003; 6(3): 189–97
  Article PubMed CAS Google Scholar
• Linden AM, Greene SJ, Bergeron M, et al. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 2004; 29(3): 502–13
  Article PubMed CAS Google Scholar
• Nordquist RE, Steckler T, Wettstein JG, et al. Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety. Psychopharmacology (Berl) 2008; 199(3): 389–402
  Article CAS Google Scholar
• Pietraszek M, Sukhanov I, Maciejak P, et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005; 514(1): 25–34
  Article PubMed CAS Google Scholar
• Steckler T, Lavreysen H, Oliveira AM, et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005; 179(1): 198–206
  Article CAS Google Scholar
• Rorick-Kehn LM, Hart JC, McKinzie DL. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl) 2005; 183(2): 226–40
  Article CAS Google Scholar
• Varty GB, Grilli M, Forlani A, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005; 179(1): 207–17
  Article CAS Google Scholar
• Satow A, Maehara S, Ise S, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methy l-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther 2008; 326(2): 577–86
  Article PubMed CAS Google Scholar
• Klodzinska A, Tatarczynska E, Stachowicz K, et al. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J Physiol Pharmacol 2004; 55 (1 Pt 1): 113–26
  PubMed CAS Google Scholar
• Lima VC, Molchanov ML, Aguiar DC, et al. Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray. Prog Neuropsycho-pharmacol Biol Psychiatry 2008; 32(1): 178–85
  CAS Google Scholar
• Brodkin J, Bradbury M, Busse C, et al. Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 2002; 16(11): 2241–4
  Article PubMed CAS Google Scholar
• Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, et al. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 2004; 47(3): 342–50
  Article PubMed CAS Google Scholar
• Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. Estrus variation in anticonflict-like effects of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of female Wistar rats. Pharmacol Biochem Behav 2006; 84(3): 385–91
  Article PubMed CAS Google Scholar
• Nordquist RE, Durkin S, Jaeschke G, et al. Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP. Eur J Pharmacol 2007; 568(1–3): 199–202
  Article PubMed CAS Google Scholar
• Spooren WP, Schoeffter P, Gasparini F, et al. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 2002; 435 (2-3): 161–70
  Google Scholar
• Spooren WP, Gasparini F, van der Putten H, et al. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 2000; 397(1): R1–2
  Article PubMed CAS Google Scholar
• Tatarczynska E, Klodzinska A, Kroczka B, et al. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacologia 2001; 158(1): 94–9
  Article CAS Google Scholar
• Wieronska JM, Smialowska M, Branski P, et al. In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 2004; 29(3): 514–21
  Article PubMed CAS Google Scholar
• Perez de la Mora M, Lara-Garcia D, Jacobsen KX, et al. Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety. Eur J Neurosci 2006; 23(10): 2749–59
  Article PubMed Google Scholar
• Schulz B, Fendt M, Gasparini F, et al. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenyl-ethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001; 41(1): 1–7
  Article PubMed CAS Google Scholar
• Iijima M, Chaki S. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacol Biochem Behav 2005; 82(4): 652–7
  Article PubMed CAS Google Scholar
• Rorick-Kehn LM, Perkins EJ, Knitowski KM, et al. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY 544344. J Pharmacol Exp Ther 2006; 316(2): 905–13
  Article PubMed CAS Google Scholar
• Helton DR, Tizzano JP, Monn JA, et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998; 284(2): 651–60
  PubMed CAS Google Scholar
• Walker DL, Rattiner LM, Davis M. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci 2002; 116(6): 1075–83
  Article PubMed CAS Google Scholar
• Tizzano JP, Griffey KI, Schoepp DD. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 2002; 73(2): 367–74
  Article PubMed CAS Google Scholar
• Linden AM, Shannon H, Baez M, et al. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psycho-pharmacology (Berl) 2005; 179(1): 284–91
  Article CAS Google Scholar
• Monn JA, Valli MJ, Massey SM, et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997; 40(4): 528–37
  Article PubMed CAS Google Scholar
• Klodzinska A, Chojnacka-Wojcik E, Palucha A, et al. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999; 38(12): 1831–9
  Article PubMed CAS Google Scholar
• Benvenga MJ, Overshiner CD, Monn JA, et al. Dis-inhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons. Drug Devel Res 1999; 47(1): 37–44
  Article CAS Google Scholar
• Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000; 39(7): 1139–46
  Article PubMed CAS Google Scholar
• Johnson MP, Baez M, Jagdmann Jr GE, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy) phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem 2003; 46(15): 3189–92
  Article PubMed CAS Google Scholar
• Johnson MP, Barda D, Britton TC, et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psycho-pharmacology (Berl) 2005; 179(1): 271–83
  Article CAS Google Scholar
• Bueno AB, Collado I, de Dios A, et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-amino-bicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem 2005; 48(16): 5305–20
  Article PubMed CAS Google Scholar
• Lin CH, Lee CC, Huang YC, et al. Activation of group II metabotropic glutamate receptors induces depotentiation in amygdala slices and reduces fear-potentiated startle in rats. Learn Mem 2005; 12(2): 130–7
  Article PubMed Google Scholar
• Iijima M, Shimazaki T, Ito A, et al. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl) 2007; 190(2): 233–9
  Article CAS Google Scholar
• Bespalov AY, van Gaalen MM, Sukhotina IA, et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol 2008; 592(1-3): 96–102
  Article PubMed CAS Google Scholar
• Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 2004; 501(1-3): 121–5
  Article PubMed CAS Google Scholar
• Yoshimizu T, Shimazaki T, Ito A, et al. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006; 186(4): 587–93
  Article CAS Google Scholar
• Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuro-pharmacology 2004; 46(4): 457–67
  CAS Google Scholar
• Stachowicz K, Klak K, Klodzinska A, et al. Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol 2004; 498(1-3): 153–6
  Article PubMed CAS Google Scholar
• Stachowicz K, Chojnacka-Wojcik E, Klak K, et al. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacol Rep 2006; 58(6): 820–6
  PubMed CAS Google Scholar
• Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004; 46(2): 151–9
  Article PubMed CAS Google Scholar
• Stachowicz K, Chojnacka-Wojcik E, Klak K, et al. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology 2007; 52(2): 306–12
  Article PubMed CAS Google Scholar
• Stachowicz K, Klak K, Pilc A, et al. Lack of the anti-anxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats. Pharmacol Rep 2005; 57(6): 856–60
  PubMed CAS Google Scholar
• Belozertseva IV, Kos T, Popik P, et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17(3): 172–9
  Article PubMed CAS Google Scholar
• Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2): 380–6
  Article PubMed CAS Google Scholar
• Smolders I, Clinckers R, Meurs A, et al. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 2008; 54(6): 1017–28
  Article PubMed CAS Google Scholar
• Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1129–35
  Article PubMed CAS Google Scholar
• Li X, Need AB, Baez M, et al. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006; 319(1): 254–9
  Article PubMed CAS Google Scholar
• Palucha A, Branski P, Szewczyk B, et al. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005; 81(4): 901–6
  Article PubMed CAS Google Scholar
• Klak K, Palucha A, Branski P, et al. Combined adminis-tration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007; 32(2): 169–72
  Article PubMed CAS Google Scholar
• Coplan JD, Mathew SJ, Smith EL, et al. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function. CNS Spectr 2001; 6(7): 607–12, 617
  PubMed CAS Google Scholar
• Grillon C, Cordova J, Levine LR, et al. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003; 168(4): 446–54
  Article CAS Google Scholar
• Bergink V, Westenberg HG. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY 354740. Int Clin Psychopharmacol 2005; 20(6): 291–3
  Article PubMed Google Scholar
• Michelson D, Levine LR, Dellva MA, et al. Clinical studies with mGlu2/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology 2005; 49(S1): 84–257
  Google Scholar
• Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008; 33(7): 1603–10
  Article PubMed CAS Google Scholar
• Rorick-Kehn LM, Johnson BG, Burkey JL, et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (−)-(1R,4S,5S,6S) -4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2007; 321(1): 308–17
  Article PubMed CAS Google Scholar
• Kellner M, Muhtz C, Stark K, et al. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/ LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 2005; 179(1): 310–5
  Article CAS Google Scholar
• Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 2008; 33(9): 2048–60
  Article PubMed CAS Google Scholar
• Berman RM, Krystal JH, Charney DS. Mechanism of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ, editor. Biology of schizophrenia and affective disorders. Washington, DC: American Psychiatric Press, 1996: 295–368
  Google Scholar
• Pilc A, Chaki S, Nowak G, et al. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008; 75(5): 997–1006
  Article PubMed CAS Google Scholar
• Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligo-dendrocytes. Biol Psychiatry 2004; 55(6): 563–9
  Article PubMed Google Scholar
• Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998; 95(22): 13290–5
  Article PubMed CAS Google Scholar
• Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705–13
  Article PubMed CAS Google Scholar
• Hasler G, Neumeister A, van der Veen JW, et al. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 2005; 58(12): 969–73
  Article PubMed CAS Google Scholar
• Hasler G, van der Veen JW, Tumonis T, et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64(2): 193–200
  Article PubMed CAS Google Scholar
• Mason G, Haga K, Appel M, et al. Measuring cortical GABA levels and neurotransmitter turnover with 1H-MRS and 13C-MRS. Biol Psychiatry 2001; 49: 148S
  Google Scholar
• Krystal JH, Sanacora G, Goddard A, et al. GABA levels and the function of glutamic acid decarboxylase in depression and panic disorder: insights from MRS. Int J Neuropsychopharmacology 2008; 11 Suppl. 1: 73
  Google Scholar
• Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target for major depressive disorder. CNS Neurol Disord Drug Targets 2007; 6(2): 101–15
  Article PubMed CAS Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47(4): 351–4
  Article PubMed CAS Google Scholar
• Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63(8): 856–64
  Article PubMed CAS Google Scholar
• Krystal JH. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 2007; 137(15-16): 215–6
  PubMed Google Scholar
• Maeng S, Zarate Jr CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63(4): 349–52
  Article PubMed CAS Google Scholar
• Paterson NE, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox Res 2007; 11(1): 1–32
  Article PubMed CAS Google Scholar
• Witkin JM, Marek GJ, Johnson BG, et al. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007; 6(2): 87–100
  Article PubMed CAS Google Scholar
• Palucha A, Pilc A. On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol J Pharmacol 2002; 54(6): 581–6
  PubMed CAS Google Scholar
• D’Ascenzo M, Fellin T, Terunuma M, et al. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc Natl Acad Sci U S A 2007; 104(6): 1995–2000
  Article PubMed CAS Google Scholar
• Legutko B, Szewczyk B, Pomierny-Chamiolo L, et al. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep 2006 May–Jun; 58(3): 427–30
  PubMed CAS Google Scholar
• Krystal JH. Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia. Biol Psychiatry 2008; 64(5): 358–60
  Article PubMed Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64(6): 468–75
  Article PubMed CAS Google Scholar
• Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5(5): 405–14
  PubMed CAS Google Scholar
• Karasawa J, Shimazaki T, Kawashima N, et al. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005; 1042(1): 92–8
  Article PubMed CAS Google Scholar